Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
NCT05784246Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2023
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of mirikizumab in ulcerative colitis (UC), sponsored by Eli Lilly and Company. Started Nov 2023; status: completed.
02
Drugs
mirikizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05784246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05784246.